65 related articles for article (PubMed ID: 3204682)
1. Clinical response to busramustine (KM-2210) in chronic lymphocytic leukemia: a pilot evaluation of estrogen receptor in relation to its therapeutic effect.
Nishikawa M; Uemura Y; Komada F; Ohno T; Katayama N; Shirakawa S
Jpn J Clin Oncol; 1988 Dec; 18(4):327-33. PubMed ID: 3204682
[TBL] [Abstract][Full Text] [Related]
2. [Clinical trial of bestrabucil (KM 2210) on hematopoietic malignancies].
Nishikawa M; Uemura Y; Matsuoka N; Ohno T; Katayama N; Tomeoku M; Kobayashi T; Kita K; Tanaka H; Minami N
Gan To Kagaku Ryoho; 1986 Jun; 13(6):2155-9. PubMed ID: 3521494
[TBL] [Abstract][Full Text] [Related]
3. [Early phase II trial of bestrabucil in hematological malignancies].
Nagura E; Ohno R; Yamada K; Akao Y; Naito K; Nishikawa M; Tanaka H; Shirakawa S; Ono Y; Ezaki K
Gan To Kagaku Ryoho; 1986 Jun; 13(6):2216-22. PubMed ID: 3459398
[TBL] [Abstract][Full Text] [Related]
4. High dose chlorambucil versus Binet's modified cyclophosphamide, doxorubicin, vincristine, and prednisone regimen in the treatment of patients with advanced B-cell chronic lymphocytic leukemia. Results of an international multicenter randomized trial. International Society for Chemo-Immunotherapy, Vienna.
Jaksic B; Brugiatelli M; Krc I; Losonczi H; Holowiecki J; Planinc-Peraica A; Kusec R; Morabito F; Iacopino P; Lutz D
Cancer; 1997 Jun; 79(11):2107-14. PubMed ID: 9179056
[TBL] [Abstract][Full Text] [Related]
5. A phase I/II study examining pentostatin, chlorambucil, and theophylline in patients with relapsed chronic lymphocytic leukemia and non-Hodgkin's lymphoma.
Willis CR; Goodrich A; Park K; Waselenko JK; Lucas M; Reese A; Diehl LF; Grever MR; Byrd JC; Flinn IW
Ann Hematol; 2006 May; 85(5):301-7. PubMed ID: 16518606
[TBL] [Abstract][Full Text] [Related]
6. [KM 2210 therapy for chronic lymphocytic leukemia].
Mori M; Murai Y; Miwa A; Fukayama M; Ikebuchi K; Nakamura N; Kaise M
Gan No Rinsho; 1983 Dec; 29(15):1788-90. PubMed ID: 6689433
[TBL] [Abstract][Full Text] [Related]
7. A phase II multi-institutional study of estra-1,3,5(10)-triene-3,17 beta-diol, 3-benzoate, 17[[4-[4-[bis(2-chloroethyl)amino]phenyl]-1- oxobutoxy]acetate] (KM2210), a novel antitumor agent, for advanced and recurrent breast carcinoma.
Kubota T; Abe O; Izuo M; Watanabe H; Enomoto K; Ohsawa N; Kuno K
Anticancer Res; 1993; 13(6B):2361-5. PubMed ID: 8135468
[TBL] [Abstract][Full Text] [Related]
8. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia.
Knauf WU; Lissichkov T; Aldaoud A; Liberati A; Loscertales J; Herbrecht R; Juliusson G; Postner G; Gercheva L; Goranov S; Becker M; Fricke HJ; Huguet F; Del Giudice I; Klein P; Tremmel L; Merkle K; Montillo M
J Clin Oncol; 2009 Sep; 27(26):4378-84. PubMed ID: 19652068
[TBL] [Abstract][Full Text] [Related]
9. Leukemic phase of B-cell lymphomas mimicking chronic lymphocytic leukemia and variants at presentation.
Nelson BP; Variakojis D; Peterson LC
Mod Pathol; 2002 Nov; 15(11):1111-20. PubMed ID: 12429788
[TBL] [Abstract][Full Text] [Related]
10. DNA-dependent protein kinase is a therapeutic target and an indicator of poor prognosis in B-cell chronic lymphocytic leukemia.
Willmore E; Elliott SL; Mainou-Fowler T; Summerfield GP; Jackson GH; O'Neill F; Lowe C; Carter A; Harris R; Pettitt AR; Cano-Soumillac C; Griffin RJ; Cowell IG; Austin CA; Durkacz BW
Clin Cancer Res; 2008 Jun; 14(12):3984-92. PubMed ID: 18559621
[TBL] [Abstract][Full Text] [Related]
11. Pentostatin (Nipent) and chlorambucil with granulocyte-macrophage colony-stimulating factor support for patients with previously untreated, treated, and fludarabine-refractory B-cell chronic lymphocytic leukemia.
Waselenko JK; Grever MR; Beer M; Lucas MA; Byrd JC
Semin Oncol; 2000 Apr; 27(2 Suppl 5):44-51. PubMed ID: 10877052
[TBL] [Abstract][Full Text] [Related]
12. Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy.
Marotta G; Bigazzi C; Lenoci M; Tozzi M; Bocchia M; Lauria F
Haematologica; 2000 Dec; 85(12):1268-70. PubMed ID: 11114133
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia.
Faderl S; Rai K; Gribben J; Byrd JC; Flinn IW; O'Brien S; Sheng S; Esseltine DL; Keating MJ
Cancer; 2006 Sep; 107(5):916-24. PubMed ID: 16832816
[TBL] [Abstract][Full Text] [Related]
14. [Clinical trial of bestrabucil (KM 2210) in hematopoietic malignancies].
Naito K; Kubo K; Akao Y; Hiraiwa A; Naoe T; Yamada K
Gan No Rinsho; 1986 Sep; 32(11):1443-50. PubMed ID: 2877106
[TBL] [Abstract][Full Text] [Related]
15. Bendamustine in the treatment of chronic lymphocytic leukemia.
Knauf W
Expert Rev Anticancer Ther; 2009 Feb; 9(2):165-74. PubMed ID: 19192955
[TBL] [Abstract][Full Text] [Related]
16. Alpha-interferon as maintenance drug after initial fludarabine therapy for patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma.
Zinzani PL; Levrero MG; Lauria F; Rondelli D; Zaja F; Russo D; Fanin R; De Rossi G; Mauro FR; Bendandi M; Gozzetti A; Dianzani F; Mandelli F; Tura S
Haematologica; 1994; 79(1):55-60. PubMed ID: 15378949
[TBL] [Abstract][Full Text] [Related]
17. [Clinical and laboratory prognostic parameters for leukemic types of chronic lymphoproliferative diseases].
Kardum-Skelin I; Planinc-Peraica A; Ostojić Kolonić S; Radić-Kristo D; Milas M; Vrhovac R; Sustercić D; Minigo H; Jaksić B
Acta Med Croatica; 2008 Oct; 62(4):351-64. PubMed ID: 19205412
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group.
Bergmann MA; Goebeler ME; Herold M; Emmerich B; Wilhelm M; Ruelfs C; Boening L; Hallek MJ;
Haematologica; 2005 Oct; 90(10):1357-64. PubMed ID: 16219572
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of 20 agents in different prognostic subgroups of chronic lymphocytic leukemia--rolipram and prednisolone active in cells from patients with poor prognosis.
Lindhagen E; Norberg M; Kanduri M; Tobin G; Säisänen L; Aberg M; Gustafsson MG; Sundström C; Rosenquist R; Aleskog A
Eur J Haematol; 2009 Jul; 83(1):22-34. PubMed ID: 19245531
[TBL] [Abstract][Full Text] [Related]
20. Mode of action of estra-1,3,5(10)-triene-3,17 beta-diol 3-benzoate 17-[4-(4-bis(2-chloroethyl)amino)phenyl)-1-oxobutoxy)acet ate) on human breast carcinoma xenografts in nude mice.
Kubota T; Koh J; Yamada Y; Oka S; Enomoto K; Ishibiki K; Abe O; Masui O; Asano K
Jpn J Cancer Res; 1988 Nov; 79(11):1224-9. PubMed ID: 3147278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
